Search results for "Ticlopidine"

showing 5 items of 25 documents

Consensus document on intermittent claudication from the Central European Vascular Forum 1st edition - Abano Terme (Italy) - May 2005 2nd revision - …

2008

Peripheral Vascular DiseasesLegtrainingTiclopidineAspirinAcetylsalicylic acidanticoagulant agentantithrombocytic agentconsensus document; intermittent claudicatio; training; antiplatelets' therapyintermittent claudicatioIntermittent ClaudicationSettore MED/11 - Malattie Dell'Apparato CardiovascolareClopidogrelantiplatelets' therapyIschemiaDisease ProgressionExercise TestHumansCarotid StenosisUltrasonography Doppler Colorconsensus documentPlatelet Aggregation Inhibitors
researchProduct

Ticlopidine in the Treatment of Multiple Atherosclerotic Arteriopathy: a Strain Gauge Plethysmography and Döppler Spectrum Analysis Evaluation

1987

The effect of ticlopidine was compared with flunarizine in patients with iliac–femoral and / or femoral–popliteal arteriosclerotic arteriopathy accompanied by lesions of the cervical arteries of no haemodynamic significance. In the lower limbs, plethysmography (strain gauge measurements) and Döppler ultrasonography integrated by spectral analysis of the cervical arteries showed qualitative and quantitative improvements of the regional haematic flow. Side-effects were negligible which suggests that ticlopidine is useful in the treatment of multiple arteriosclerotic arteriopathy.

medicine.medical_specialtyPathologyTiclopidineArteriosclerosisCervical ArteryHemodynamics030204 cardiovascular system & hematologyBiochemistry03 medical and health sciencessymbols.namesake0302 clinical medicineInternal medicineHumansMedicinePlethysmograph030212 general & internal medicineTiclopidineFlunarizineAgedUltrasonographybusiness.industryVascular diseaseBiochemistry (medical)Cell BiologyGeneral MedicineMiddle Agedmedicine.diseasePlethysmographyCardiologysymbolsbusinessDoppler effectBlood Flow VelocityFlunarizinemedicine.drugStrain gauge plethysmographyJournal of International Medical Research
researchProduct

Antiplatelet treatment in ischemic stroke treatment.

2009

Antiplatelets represent a diverse group of agents that share the ability to reduce platelet activity through a variety of mechanisms. Antithrombotic agents are effective in the secondary prevention of ischemic strokes. Most strokes are caused by a sudden blockage of an artery in the brain (called an ischaemic stroke) that is usually due to a blood clot. Immediate treatment with antiplatelet drugs such as aspirin may prevent new clots from forming and hence improve recovery after stroke. Several studies have evaluated the role of one antiplatelet agent, aspirin, in reducing stroke severity. The International Stroke Trial (IST) of 20,000 patients with acute stroke from other countries. In thi…

medicine.medical_specialtySettore MED/09 - Medicina InternaTiclopidineBrain IschemiaInternal medicineDrug DiscoveryAntithromboticmedicineHumanscardiovascular diseasesPlatelet activationTiclopidineStrokeAspirinAspirinbusiness.industryGeneral Medicinemedicine.diseaseClopidogrelSurgeryClopidogrelStrokemedicine.anatomical_structureToxicityCardiologyantiplatelets strokeprevention treatmentbusinessPlatelet Aggregation Inhibitorsmedicine.drugArteryCurrent topics in medicinal chemistry
researchProduct

Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation.

1998

Background —This study was performed to analyze the influence of either aspirin, ticlopidine, or their combination on platelet activation and aggregation parameters after stent implantation. Methods and Results —Sixty-one patients with successful implantation of a single Palmaz-Schatz stent in a native coronary artery were randomly assigned to either group A (aspirin 300 mg/d+ticlopidine 2×250 mg/d), group B (ticlopidine 2×250 mg/d), or group C (aspirin 300 mg/d). Platelet activation was evaluated on days 1, 7, and 14 by flow cytometry measurement of expression of CD62p (p-selectin) and the binding of fibrinogen to the platelet surface glycoprotein IIb/IIIa receptor. Platelet aggregation w…

medicine.medical_specialtyTiclopidineTime FactorsPlatelet Aggregationmedicine.medical_treatmentUrologyCoronary DiseasePlatelet Glycoprotein GPIIb-IIIa ComplexFibrinogenPhysiology (medical)MedicineHumansPlateletPlatelet activationTiclopidineAngioplasty Balloon CoronaryAspirinChemotherapyAspirinbusiness.industryStentFibrinogenP-SelectinAnesthesiaPlatelet aggregation inhibitorDrug Therapy CombinationStentsCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugCirculation
researchProduct

Platelet Function During Ticlopidine and Eicosapentaenoic Acid Administration in Patients with Coronary Heart Disease

2010

Antiplatelet drugs have been reported to be useful in unstable angina. This study was designed to investigate the effects of simultaneous administration of ticlopidine and eicosapentaenoic acid (EPA) on platelet function in coronary heart disease (CHD) patients. Ticlopidine significantly reduced platelet aggregation induced by ADP and collagen with no effect on arachidonate metabolism. The aggregation responses to collagen, ADP and arachidonate were not altered significantly by EPA (as fish oil) intake whereas thromboxane A(2) formation was reduced, but not completely inhibited. Combined therapy seems to achieve a more marked degree of inhibition of aggregation together with a fall in the u…

medicine.medical_specialtyUnstable anginabusiness.industryMetaboliteHematologyGeneral MedicinePharmacologyFish oilmedicine.diseaseEicosapentaenoic acidchemistry.chemical_compoundThromboxane A2chemistryInternal medicinemedicineCardiologyPlateletPlatelet activationTiclopidinebusinessmedicine.drugPlatelets
researchProduct